7PUD
 
 | | Bryoporin - actinoporin from moss Physcomitrium patens | | Descriptor: | (4S)-2-METHYL-2,4-PENTANEDIOL, Bryoporin, SULFATE ION | | Authors: | Solinc, G, Anderluh, G, Podobnik, M. | | Deposit date: | 2021-09-29 | | Release date: | 2022-09-28 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (1.25 Å) | | Cite: | Pore-forming moss protein bryoporin is structurally and mechanistically related to actinoporins from evolutionarily distant cnidarians.
J.Biol.Chem., 298, 2022
|
|
6LK4
 | | Crystal structure of GMP reductase from Trypanosoma brucei in complex with guanosine 5'-triphosphate | | Descriptor: | GUANOSINE-5'-TRIPHOSPHATE, Guanosine 5'-monophosphate Reductase, PHOSPHATE ION | | Authors: | Mase, H, Otani, T, Imamura, A, Nishimura, S, Inui, T. | | Deposit date: | 2019-12-18 | | Release date: | 2020-03-18 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.503 Å) | | Cite: | Allosteric regulation accompanied by oligomeric state changes of Trypanosoma brucei GMP reductase through cystathionine-beta-synthase domain.
Nat Commun, 11, 2020
|
|
4YB9
 | | Crystal structure of the Bovine Fructose transporter GLUT5 in an open inward-facing conformation | | Descriptor: | Solute carrier family 2, facilitated glucose transporter member 5 | | Authors: | Verdon, G, Kang, H.J, Iwata, S, Drew, D. | | Deposit date: | 2015-02-18 | | Release date: | 2015-10-14 | | Last modified: | 2024-05-01 | | Method: | X-RAY DIFFRACTION (3.2 Å) | | Cite: | Structure and mechanism of the mammalian fructose transporter GLUT5.
Nature, 526, 2015
|
|
4YBQ
 | | Rat GLUT5 with Fv in the outward-open form | | Descriptor: | Solute carrier family 2, facilitated glucose transporter member 5, antibody Fv fragment heavy chain, ... | | Authors: | Nomura, N, Shimamura, T, Iwata, S. | | Deposit date: | 2015-02-19 | | Release date: | 2015-10-07 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (3.27 Å) | | Cite: | Structure and mechanism of the mammalian fructose transporter GLUT5
Nature, 526, 2015
|
|
9CGQ
 | |
9CGP
 | |
1MPT
 | | CRYSTAL STRUCTURE OF A NEW ALKALINE SERINE PROTEASE (M-PROTEASE) FROM BACILLUS SP. KSM-K16 | | Descriptor: | CALCIUM ION, M-PROTEASE | | Authors: | Yamane, T, Kani, T, Hatanaka, T, Suzuki, A, Ashida, T, Kobayashi, T, Ito, S, Yamashita, O. | | Deposit date: | 1994-04-13 | | Release date: | 1994-06-22 | | Last modified: | 2024-02-14 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Structure of a new alkaline serine protease (M-protease) from Bacillus sp. KSM-K16.
Acta Crystallogr.,Sect.D, 51, 1995
|
|
5UVC
 | | Design, Synthesis, and Evaluation of the First Selective and Potent G-protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure | | Descriptor: | Beta-adrenergic receptor kinase 1, N-benzyl-3-({[5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]methyl}amino)benzamide, SULFATE ION | | Authors: | Hoffman, I.D, Lawson, J.D. | | Deposit date: | 2017-02-20 | | Release date: | 2017-07-26 | | Last modified: | 2024-03-06 | | Method: | X-RAY DIFFRACTION (2.65 Å) | | Cite: | Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure.
J. Med. Chem., 60, 2017
|
|
5UUU
 | | Design, Synthesis, and Evaluation of the First Selective and Potent G-protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure | | Descriptor: | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, 3-({[4-methyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]methyl}amino)-N-[2-(trifluoromethyl)benzyl]benzamide, Beta-adrenergic receptor kinase 1, ... | | Authors: | Hoffman, I.D, Lawson, J.D. | | Deposit date: | 2017-02-17 | | Release date: | 2017-07-26 | | Last modified: | 2024-03-06 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure.
J. Med. Chem., 60, 2017
|
|
6NZT
 | |
6NZV
 | | Crystal structure of HCV NS3/4A protease in complex with compound 12 | | Descriptor: | (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide, HCV NS3/4A protease, SULFATE ION, ... | | Authors: | Appleby, T.C, Taylor, J.G. | | Deposit date: | 2019-02-14 | | Release date: | 2019-07-10 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (1.55 Å) | | Cite: | Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®.
Bioorg.Med.Chem.Lett., 29, 2019
|
|
4I3B
 | | Crystal structure of fluorescent protein UnaG wild type | | Descriptor: | 3-[5-[(Z)-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-2-[[5-[(Z)-(3-ethenyl-4-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-1H-pyrrol-2-yl]methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid, Bilirubin-inducible fluorescent protein UnaG, DI(HYDROXYETHYL)ETHER | | Authors: | Kumagai, A, Ando, R, Miyatake, H, Miyawaki, A. | | Deposit date: | 2012-11-26 | | Release date: | 2013-06-19 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (1.199 Å) | | Cite: | A bilirubin-inducible fluorescent protein from eel muscle
Cell(Cambridge,Mass.), 153, 2013
|
|
4I3D
 | | Crystal structure of fluorescent protein UnaG N57A mutant | | Descriptor: | 3-[5-[(Z)-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-2-[[5-[(Z)-(3-ethenyl-4-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-1H-pyrrol-2-yl]methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid, Bilirubin-inducible fluorescent protein UnaG | | Authors: | Kumagai, A, Ando, R, Miyatake, H, Miyawaki, A. | | Deposit date: | 2012-11-26 | | Release date: | 2013-06-19 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (2.298 Å) | | Cite: | A bilirubin-inducible fluorescent protein from eel muscle
Cell(Cambridge,Mass.), 153, 2013
|
|
4I3C
 | | Crystal structure of fluorescent protein UnaG N57Q mutant | | Descriptor: | 3-[5-[(Z)-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-2-[[5-[(Z)-(3-ethenyl-4-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-1H-pyrrol-2-yl]methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid, Bilirubin-inducible fluorescent protein UnaG | | Authors: | Kumagai, A, Ando, R, Miyatake, H, Miyawaki, A. | | Deposit date: | 2012-11-26 | | Release date: | 2013-06-19 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (2.001 Å) | | Cite: | A bilirubin-inducible fluorescent protein from eel muscle
Cell(Cambridge,Mass.), 153, 2013
|
|
5EC5
 | | Crystal structure of lysenin pore | | Descriptor: | Lysenin, MERCURIBENZOIC ACID, MERCURY (II) ION | | Authors: | Podobnik, M, Savory, P, Rojko, N, Kisovec, M, Bruce, M, Jayasinghe, L, Anderluh, G. | | Deposit date: | 2015-10-20 | | Release date: | 2016-05-18 | | Last modified: | 2024-05-08 | | Method: | X-RAY DIFFRACTION (3.1 Å) | | Cite: | Crystal structure of an invertebrate cytolysin pore reveals unique properties and mechanism of assembly.
Nat Commun, 7, 2016
|
|
6MOA
 | | C-terminal bromodomain of human BRD2 in complex with 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole inhibitor | | Descriptor: | 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole, Bromodomain-containing protein 2, GLYCEROL | | Authors: | Lansdon, E.B, Newby, Z.E.R. | | Deposit date: | 2018-10-04 | | Release date: | 2019-01-23 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (1.271 Å) | | Cite: | Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
Bioorg. Med. Chem., 27, 2019
|
|
6MO7
 | | N-terminal bromodomain of human BRD2 with N-((4-(3-(N-cyclopentylsulfamoyl)-4-methylphenyl)-3-methylisoxazol-5-yl)methyl)acetamide inhibitor | | Descriptor: | Bromodomain-containing protein 2, N-({4-[3-(cyclopentylsulfamoyl)-4-methylphenyl]-3-methyl-1,2-oxazol-5-yl}methyl)acetamide | | Authors: | Lansdon, E.B, Newby, Z.E.R. | | Deposit date: | 2018-10-04 | | Release date: | 2019-01-23 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (1.85 Å) | | Cite: | Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
Bioorg. Med. Chem., 27, 2019
|
|
6MO8
 | | N-terminal bromodomain of human BRD2 in complex with 4,4'-(quinoline-5,7-diyl)bis(3,5-dimethylisoxazole) inhibitor | | Descriptor: | 5,7-bis(3,5-dimethyl-1,2-oxazol-4-yl)quinoline, Bromodomain-containing protein 2, SULFATE ION | | Authors: | Lansdon, E.B, Newby, Z.E.R. | | Deposit date: | 2018-10-04 | | Release date: | 2019-01-23 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
Bioorg. Med. Chem., 27, 2019
|
|
6MO9
 | | N-terminal bromodomain of human BRD2 in complex with N-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)quinoline-5-sulfonamide inhibitor | | Descriptor: | Bromodomain-containing protein 2, N-cyclopentyl-7-(3,5-dimethyl-1,2-oxazol-4-yl)quinoline-5-sulfonamide | | Authors: | Lansdon, E.B, Newby, Z.E.R. | | Deposit date: | 2018-10-04 | | Release date: | 2019-01-23 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (1.801 Å) | | Cite: | Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
Bioorg. Med. Chem., 27, 2019
|
|
6JIG
 | | Crystal structure of GMP reductase C318A from Trypanosoma brucei in complex with guanosine 5'-monophosphate | | Descriptor: | GMP reductase, GUANOSINE-5'-MONOPHOSPHATE, POTASSIUM ION | | Authors: | Mase, H, Imamura, A, Nishimura, S, Inui, T. | | Deposit date: | 2019-02-21 | | Release date: | 2020-02-26 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.903 Å) | | Cite: | Allosteric regulation accompanied by oligomeric state changes of Trypanosoma brucei GMP reductase through cystathionine-beta-synthase domain.
Nat Commun, 11, 2020
|
|
6JL8
 | |
6KO5
 | | Complex structure of Ghrelin receptor with Fab | | Descriptor: | 6-(4-bromanyl-2-fluoranyl-phenoxy)-2-methyl-3-[[(3~{S})-1-propan-2-ylpiperidin-3-yl]methyl]pyrido[3,2-d]pyrimidin-4-one, Chimera of Soluble cytochrome b562 and Growth hormone secretagogue receptor type 1, Fab7881 Heavy Chain, ... | | Authors: | Shiimura, Y, Horita, S, Asada, H, Hirata, K, Iwata, S, Kojima, M. | | Deposit date: | 2019-08-08 | | Release date: | 2020-08-12 | | Last modified: | 2024-11-20 | | Method: | X-RAY DIFFRACTION (3.3 Å) | | Cite: | Structure of an antagonist-bound ghrelin receptor reveals possible ghrelin recognition mode.
Nat Commun, 11, 2020
|
|
6KS2
 | | Structure of anti-Ghrelin receptor antibody | | Descriptor: | Fab7881 Heavy Chain (FabH), Fab7881 Light Chain (FabL) | | Authors: | Shiimura, Y, Horita, S, Asada, H, Hirata, K, Iwata, S, Kojima, M. | | Deposit date: | 2019-08-23 | | Release date: | 2020-08-12 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (1.753 Å) | | Cite: | Structure of an antagonist-bound ghrelin receptor reveals possible ghrelin recognition mode.
Nat Commun, 11, 2020
|
|
7W6Z
 | |
7W71
 | |
